FIELD: medicine.
SUBSTANCE: invention relates to medicine and pharmaceuticals. 1 object is a method of treating gastric cancer in a human subject, comprising administering to the subject a therapeutically effective amount of an antibody to fibroblast growth factor receptor 2 IIIb (anti-FGFR2-IIIb) and applying a modified FOLFOX6 chemotherapy regimen (mFOLFOX6), where the antibody to FGFR2-IIIb is afucosylated, where (1) anti-FGFR2-IIIb antibody is administered at a dose of 6–15 mg/kg, (2) at least one intermediate dose of anti-FGFR2-IIIb antibody is administered between two doses (1), (3) mFOLFOX6 chemotherapy includes administration of 50–100 mg/m2 of oxaliplatin, 100–400 mg/m2 of leucovorin and 100–400 mg/m2 of 5-fluorouracil (5-FU) by intravenous infusion or intravenous bolus injection followed by 2,200–2,400 mg/m2 of 5-FU for 44–48 hours, and (4) introduction of antibodies to FGFR2-IIIb according to (1) and mFOLFOX6 according to (3) are carried out simultaneously or sequentially once every 13–15 days. Object 2 is a method of treating locally advanced, unresectable or metastatic gastric cancer that overexpresses FGFR2-IIIb in a human subject.
EFFECT: treatment of gastric cancer using the claimed mode of administration of the FGFR2-IIIb antibody in combination with chemotherapy according to the mFOLFOX6 scheme.
43 cl, 3 dwg, 8 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| AFUCOSYLATED FIBROBLAST GROWTH FACTOR FGFR2IIIB RECEPTOR | 2014 |
|
RU2740714C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| DOSES AND ADMINISTRATION OF ANTIBODIES AGAINST C5 FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) | 2020 |
|
RU2822664C2 |
| HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
| COMPOSITION FOR PREVENTION OR TREATMENT OF IL-8-RELATED DISEASES | 2017 |
|
RU2766112C2 |
| ANTI-TIM3 ANTIBODIES AND METHODS FOR USING THEM | 2015 |
|
RU2723708C2 |
| PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
